$BLRX News
Last published 2w ago
- 2w agoBLRXBioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026PR NewswireGLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of
- 1mo agoBLRXBioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education DayPR NewswireTEL AVIV, Israel and OSLO, Norway, Oct. 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and
- 2mo agoBLRXBioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2mo agoBLRXBioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2mo agoBLRXBioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private PlacementPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing...
- 2mo agoBLRXBioLineRx to Report Second Quarter 2026 Results on August 31, 2026PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 3mo agoBLRXBioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 4mo agoBLRXBioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft ModelPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 5mo agoBLRXBioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 5mo agoBLRXBioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual MeetingPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 5mo agoBLRXBioLineRx to Report First Quarter 2026 Results on May 27, 2026PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 5mo agoBLRXBioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived XenograftsPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and...
- 6mo agoBLRXBioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and...
- 7mo agoBLRXBioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and...
- 7mo agoBLRXBioLineRx Reports 2025 Financial Results and Provides Corporate UpdatePR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 8mo agoBLRXBioLineRx to Report 2025 Annual Results on March 23, 2026PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and...
- 11mo agoBLRXBioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 11mo agoBLRXHemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid TumorsBusiness WirePatent protects the use of GLIX1 in cancers where cytidine deaminase (CDA) is not over-expressed — representing more than 90% of all cancer types Hemispherian AS, a biotechnology company pioneering first-in-class
- 11mo agoBLRXBioLineRx to Report Third Quarter 2025 Results on November 24, 2025PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 11mo agoBLRXBioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer TypesPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and...
- 1y agoBLRXBioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other CancersPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and...
- 1y agoBLRXBioLineRx Ltd. (BLRX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoBLRXBioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 1y agoBLRXBioLineRx to Report Second Quarter 2025 Results on August 14, 2025PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 1y agoBLRXBioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual MeetingPR NewswireBioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease,...
- 1y agoBLRXBioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 1y agoBLRXBioLineRx to Report First Quarter 2025 Results on May 27, 2025PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 1y agoBLRXBioLineRx Reports 2024 Financial Results and Provides Corporate UpdatePR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 1y agoBLRXBioLineRx to Report 2024 Annual Results on March 31, 2025PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 1y agoALLTBLRXCGENCGNT+2Cognyte Elects Two New Board Members to Strengthen Expertise and Drive GrowthBusiness WireAnnouncement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global
- 1y agoBLRXBioLineRx Issues Letter to ShareholdersPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 1y agoBLRXBioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary SharesPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 1y agoBLRXBioLineRx Announces $10 Million Registered Direct OfferingPR NewswireBioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing...
- 1y agoBLRXSLXNSilexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of DirectorsGlobeNewswireCayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced
- 1y agoBLRXBioLineRx Ltd. (BLRX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoBLRXBioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder ValuePR NewswireBioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases,...
- 1y agoBLRXBioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 1y agoBLRXBioLineRx to Report Third Quarter 2024 Results on November 25, 2024PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2y agoBLRXBioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2y agoBLRXBioLineRx Announces USPTO Allowance of New Composition of Matter Patent on MotixafortidePR NewswireBioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases,...
- 2y agoBLRXBioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell CollectionPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2y agoBLRXBioLineRx Ltd. (BLRX) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBLRXBioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio UpdatesPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2y agoBLRXBioLineRx to Report Second Quarter 2024 Results on August 15, 2024PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2y agoBLRXBioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2y agoBLRXBioLineRx Ltd. (BLRX) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBLRXBioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio UpdatesPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2y agoBLRXBioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual MeetingPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2y agoBLRXBioLineRx to Report First Quarter 2024 Results on May 28, 2024PR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- 2y agoBLRXBioLineRx Announces Receipt of Nasdaq Minimum Bid Price NotificationPR NewswireBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...